BSE filing, NSE: ALIVUS. Summary written from the filing by ALFA Finder's alert engine.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,399.40
- Market cap
- ₹17,181 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.5×Sector 46.1×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Alivus Life Sciences Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Alivus Life Sciences Legal & Regulatory
Alivus Life Sciences Limited received a GST order for FY 2020-22 involving a tax demand and penalty of Rs. 0.51 Crore. The company is currently assessing an appeal.
- Value
- ₹0.51 Cr
Alivus Life Sciences Acquisition Worth ₹14.04 Cr
Alivus Life Sciences acquired a 9.21% stake in Torrent Urja 19 Private Limited for Rs. 14.04 Crore. The investment supports its renewable energy and carbon neutrality goals.
- Value
- ₹14.04 Cr
Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Other debt & borrowing announcements
All →Poonawalla Fincorp Debt & Borrowing: ₹1,318 Cr
Poonawalla Fincorp allotted Rs 1,318 Crore NCDs across two series G1 and G2. The allotment comprises zero-coupon and 9% coupon debentures maturing by 2030.
- Value
- ₹1,318 Cr
Fusion Finance Debt & Borrowing: ₹1.35 Cr
Fusion Finance Limited paid Rs.1.35 Crore monthly interest on its non-convertible debentures on 28 October 2026. The payment was made on time, one day ahead of the stated due date of 29 October 2026.
- Value
- ₹1.35 Cr
Bajaj Finance Debt & Borrowing: ₹300 Cr
Bajaj Life Insurance purchased 30,000 NCDs of Bajaj Finance worth ₹300 Crore on NSE. The open-market debt buy signals promoter confidence in the company.
- Value
- ₹300.0 Cr
Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr